Was drug trial payment too high?
Documents obtained by the Â鶹¹ÙÍøÊ×Ò³Èë¿Ú under freedom of information raise new questions about the medical drug trial in March which .
The trial, which involved an anti-inflammatory drug called TGN1412 that had never previously been given to humans, was approved by Brent Medical Ethics Committee. The Committee's minutes show that Committee members initially had doubts about the sum of £2,000 paid to the volunteers. They felt that the payment was high in comparison with other similar studies and were concerned that the payment might be higher than normal in order to induce recruitment into the study.
The committee was given two reasons for the figure - that the study involved 'a totally novel drug and mode of action' and that the follow-up period was longer than usual.
Parexel, the research company running the trial, responded by submitting a breakdown of the £2,000 fee to the Committee. The Committee then approved the trial.
A 
°ä´Ç³¾³¾±ð²Ô³Ù²õÌýÌý Post your comment